Patients or physicians interested in participating in any of our clinical protocols should contact the company, not the investigators:
E-mail: MedicalAffairs@pcyc.com
Phone: 1-408-774-0330
Details of the clinical protocols can be found in the www.clinicaltrials.gov database.
Patients or physicians interested in participating in any of our clinical protocols should contact the company, not the investigators:
E-mail: MedicalAffairs@pcyc.com
Phone: 1.408.774.0330
Details of the clinical protocols can be found in the www.clinicaltrials.gov database.
- Phase 1/2 Trial of MGd and Radiation Therapy in Newly Diagnosed Glioblastoma Multiforme (RTOG/NCI-sponsored trial)
- Phase 2 Trial of MGd and Radiation Therapy in Pediatric Glioma (NCI-sponsored trial)
- Phase 2 Trial of the Histone Deacetylase (HDAC) Inhibitor PCI-24781 for Treatment of Lymphoma
- Phase 1 Trial of the Safety and Tolerability of Oral Capsule Form of PCI-24781 in Advanced Cancer Patients
Because these drugs are investigational, they can only be used in clinical trials approved by the U.S. Food and Drug Administration (FDA) and by Institutional Review Boards of the individual institutions carrying out the trials. No benefit can be guaranteed from the use of investigational drugs, and only a qualified medical professional can determine who is and who is not a candidate to participate in these clinical trials.